Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
Start Date
9/15/2023
Completion Date
10/1/2028
Summary
Part A of this trial will evaluate the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos Delivery Device, together with the Precision Delivery Mechanism, to safely achieve the intended product performance.
Detailed Description
The following two dose levels will be tested: * Up to 4.1E11 total vg/cochlea * Up to 8.1E11 total vg/cochlea
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
AAVAnc80-hOTOF via Akouos Delivery Device
AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Conditions
Locations
University of California, San Francisco Benioff Children's Hospital
San Francisco, California 94158
United States
University of Iowa
Iowa City, Iowa 52242
United States
Boston Children's Hospital
Boston, Massachusetts 02115
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania 19146
United States
Vanderbilt Bill Wilkerson Center
Nashville, Tennessee 37232
United States
The Hospital for Sick Children Jaina.negandhi@sickkids.ca +1 (416) 813 6683
Toronto, Ontario M5G 1X8
Canada
National Taiwan University Hospital
Taipei, 100
Taiwan
University College London
London, United Kingdom NW1 2PG
United Kingdom